To evaluate the contribution of each agent to the effect of combination synergy, we analysed our breast cancer cell line panel screening data and found that sensitivity to TRAIL as a single agent is a re-requisite and was strongly correlated with synergy of the combined AZD5582+TRAIL treatment, P<0.0001 (Figure 3a), however, sensitivity to AZD5582 did not, P=0.99 (Figure 3b). Here, TNFSF10 is linked to breast carcinoma.